ASH: CAR T-Cell Tx Offers Durable Response in Pre-Treated MM – MedPage Today
Medical Xpress |
ASH: CAR T-Cell Tx Offers Durable Response in Pre-Treated MM
MedPage Today ATLANTA – A single infusion of a gene therapy called bb2121 showed promise in heavily pre-treated multiple myeloma patients, offering a complete response that was sustained for beyond a year in some cases, researchers reported here. Of 18 patients … ‘Unheard of’ responses to bluebird CAR–T therapy seen in myeloma studyReuters CAR T, immunotherapy bring new hope for multiple myeloma patientsMedical Xpress #ASH17: The BCMA-targeted CAR–T bb2121 from bluebird and Celgene takes a star turn in the spotlightEndpoints News OncLive –Business Wire (press release) all 23 news articles » |
Nasdaq |
Editas Medicine Reports Data Supporting Multiple Approaches to Create Treatments for Sickle Cell Disease and Beta …
GlobeNewswire (press release) CAMBRIDGE, Mass., Dec. 11, 2017 (GLOBE NEWSWIRE) — Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced results from experiments to demonstrate expanded CRISPR genome editing strategies in hematopoietic stem cells for … Editas Medicine Out with News, Shares DropBaystreet.ca Zacks’ 7 Best Strong Buys for 2018Zacks.com |
WIRED |
Crispr Therapeutics Plans Its First Clinical Trial for Genetic Disease
WIRED In late 2012, French microbiologist Emmanuelle Charpentier approached a handful of American scientists about starting a company, a Crispr company. They included UC Berkeley’s Jennifer Doudna, George Church at Harvard University, and his former postdoc … CRISPR: Five Ways to Maximize Its PotentialR & D Magazine |
|
Mustang Bio’s MB-102 (CD123 CAR) CAR T Therapy Achieves Complete Response in Acute Myeloid Leukemia and …
Nasdaq NEW YORK, Dec. 11, 2017 (GLOBE NEWSWIRE) — Mustang Bio, Inc. (“Mustang”) (NASDAQ:MBIO), a Fortress Biotech (NASDAQ:FBIO) Company focused on the development of novel immunotherapies based on proprietary chimeric antigen receptor engineered T cell (“CAR … Fortress Biotech Announces Positive Clinical Data From Fortress …GlobeNewswire (press release) |
|
Mustang Bio’s MB-102 (CD123 CAR) CAR T Therapy Achieves Complete Response in Acute Myeloid Leukemia and …
Nasdaq NEW YORK, Dec. 11, 2017 (GLOBE NEWSWIRE) — Mustang Bio, Inc. (“Mustang”) (NASDAQ:MBIO), a Fortress Biotech (NASDAQ:FBIO) Company focused on the development of novel immunotherapies based on proprietary chimeric antigen receptor engineered T cell (“CAR … Fortress Biotech Announces Positive Clinical Data From Fortress …GlobeNewswire (press release) |
|
Mustang Bio’s MB-102 (CD123 CAR) CAR T Therapy Achieves Complete Response in Acute Myeloid Leukemia and …
GlobeNewswire (press release) NEW YORK, Dec. 11, 2017 (GLOBE NEWSWIRE) — Mustang Bio, Inc. (“Mustang”) (NASDAQ:MBIO), a Fortress Biotech (NASDAQ:FBIO) Company focused on the development of novel immunotherapies based on proprietary chimeric antigen receptor engineered T cell (“CAR … Fortress Biotech Announces Positive Clinical Data From Fortress Companies Presented at the 59th American Society …Nasdaq |